Article Information
History
- August 7, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- James Monkman1,
- Honesty Kim2,
- Aaron Mayer2,
- Ahmed Mehdi3,
- Nicholas Matigian3,
- Marie Cumberbatch4,
- Milan Bhagat4,
- Rahul Ladwa5,6,
- Scott N Mueller7,
- Mark N Adams1,
- Ken O’Byrne1,5,* and
- Arutha Kulasinghe1,6,8,*
- 1Queensland University of Technology, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Brisbane, QLD, Australia
- 2Enable Medicine, Menlo Park, CA, USA
- 3QFAB Bioinformatics, The University of Queensland, Brisbane, QLD, Australia
- 4Tristar Technologies Group, Rockville, MD, USA
- 5Princess Alexandra Hospital, Brisbane, QLD, Australia
- 6University of Queensland, Faculty of Medicine, Brisbane, QLD, Australia
- 7Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia
- 8University of Queensland, Institute of Molecular Biosciences, QLD, Australia
- ↵*Corresponding Authors: Dr Arutha Kulasinghe: Arutha.kulasinghe{at}qut.edu.au; Prof Ken O’Byrne: k.obyrne{at}qut.edu.au, Address: Queensland University of Technology, Centre for Genomics and Personalised Health, School of Biomedical Sciences, 37 Kent Street, Woolloongabba, QLD 4102, Australia.
Posted August 07, 2021.
IL-2 stromal signatures dissect immunotherapy response groups in non-small cell lung cancer (NSCLC)
